Zealand Pharma Valuation
Is ZEALC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ZEALC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ZEALC (DKK659) is trading below our estimate of fair value (DKK2000.71)
Significantly Below Fair Value: ZEALC is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZEALC?
Key metric: As ZEALC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
What is ZEALC's PB Ratio? | |
---|---|
PB Ratio | 5.4x |
Book | DKK 8.62b |
Market Cap | DKK 46.84b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 609.1x |
Enterprise Value/EBITDA | -30.3x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ZEALC's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 6.7x | ||
GNS Genus | 2.3x | 49.7% | UK£1.1b |
OXB Oxford Biomedica | 5.3x | 96.4% | UK£347.6m |
BVXP Bioventix | 12.6x | n/a | UK£152.7m |
FARN Faron Pharmaceuticals Oy | n/a | 33.9% | UK£180.5m |
ZEALC Zealand Pharma | 5.4x | 24.6% | DKK 46.8b |
Price-To-Book vs Peers: ZEALC is expensive based on its Price-To-Book Ratio (5.4x) compared to the peer average (-0.5x).
Price to Book Ratio vs Industry
How does ZEALC's PB Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Book vs Industry: ZEALC is expensive based on its Price-To-Book Ratio (5.4x) compared to the UK Biotechs industry average (2.8x).
Price to Book Ratio vs Fair Ratio
What is ZEALC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 5.4x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ZEALC's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | DKK 659.00 | DKK 966.00 +46.6% | 11.1% | DKK 1,100.00 | DKK 750.00 | n/a | 12 |
Feb ’26 | n/a | DKK 1,007.64 0% | 9.4% | DKK 1,100.00 | DKK 750.00 | n/a | 11 |
Jan ’26 | n/a | DKK 1,012.18 0% | 9.6% | DKK 1,100.00 | DKK 750.00 | n/a | 11 |
Dec ’25 | n/a | DKK 1,015.00 0% | 10.4% | DKK 1,100.00 | DKK 815.00 | n/a | 11 |
Nov ’25 | DKK 823.50 | DKK 1,007.89 +22.4% | 11.7% | DKK 1,106.00 | DKK 800.00 | n/a | 9 |
Oct ’25 | DKK 821.75 | DKK 1,022.29 +24.4% | 10.3% | DKK 1,106.00 | DKK 800.00 | n/a | 7 |
Sep ’25 | DKK 885.50 | DKK 1,015.14 +14.6% | 10.0% | DKK 1,106.00 | DKK 800.00 | n/a | 7 |
Aug ’25 | DKK 911.00 | DKK 989.86 +8.7% | 9.6% | DKK 1,100.00 | DKK 800.00 | n/a | 7 |
Jul ’25 | n/a | DKK 918.00 0% | 12.2% | DKK 1,100.00 | DKK 800.00 | n/a | 6 |
Jun ’25 | DKK 628.50 | DKK 785.57 +25.0% | 8.9% | DKK 840.00 | DKK 625.00 | n/a | 7 |
May ’25 | DKK 625.00 | DKK 782.00 +25.1% | 10.0% | DKK 840.00 | DKK 600.00 | n/a | 7 |
Apr ’25 | DKK 684.25 | DKK 754.29 +10.2% | 14.4% | DKK 840.00 | DKK 570.00 | n/a | 7 |
Mar ’25 | DKK 659.00 | DKK 598.67 -9.2% | 26.1% | DKK 800.00 | DKK 382.00 | DKK 659.00 | 6 |
Feb ’25 | n/a | DKK 423.33 0% | 11.2% | DKK 485.00 | DKK 355.00 | n/a | 6 |
Jan ’25 | DKK 361.10 | DKK 379.00 +5.0% | 11.7% | DKK 430.00 | DKK 295.00 | n/a | 6 |
Dec ’24 | DKK 336.50 | DKK 365.33 +8.6% | 9.3% | DKK 400.00 | DKK 295.00 | n/a | 6 |
Nov ’24 | DKK 288.80 | DKK 343.83 +19.1% | 9.3% | DKK 380.00 | DKK 295.00 | DKK 823.50 | 6 |
Oct ’24 | n/a | DKK 343.83 0% | 9.3% | DKK 380.00 | DKK 295.00 | DKK 821.75 | 6 |
Sep ’24 | n/a | DKK 314.50 0% | 12.5% | DKK 380.00 | DKK 270.00 | DKK 885.50 | 6 |
Aug ’24 | n/a | DKK 295.17 0% | 11.4% | DKK 340.00 | DKK 235.00 | DKK 911.00 | 6 |
Jul ’24 | DKK 245.00 | DKK 295.17 +20.5% | 11.4% | DKK 340.00 | DKK 235.00 | n/a | 6 |
Jun ’24 | n/a | DKK 295.17 0% | 11.4% | DKK 340.00 | DKK 235.00 | DKK 628.50 | 6 |
May ’24 | DKK 242.20 | DKK 291.83 +20.5% | 11.3% | DKK 340.00 | DKK 235.00 | DKK 625.00 | 6 |
Apr ’24 | DKK 215.20 | DKK 294.20 +36.7% | 11.3% | DKK 333.00 | DKK 235.00 | DKK 684.25 | 5 |
Mar ’24 | DKK 228.40 | DKK 257.33 +12.7% | 5.3% | DKK 275.00 | DKK 235.00 | DKK 659.00 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/28 22:30 |
End of Day Share Price | 2025/02/28 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Laura Hindley | Berenberg |
Kerry Holford | Berenberg |
Charlie Haywood | BofA Global Research |